ESMO Congress 2021
ESMO 2021 Prostate Cancer
- ESMO 2021: A First-in-Human Study of FOR46 in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)
- ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer (mHSPC)
- ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer (mCSPC)
- ESMO 2021: PSMAddition: A Phase III Trial to Compare Treatment with 177Lu-PSMA-617 plus Standard of Care (SOC) Versus SOC Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer
- ESMO 2021: PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment with a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients with mCRPC
ESMO 2021 Bladder Cancer
- ESMO 2021: Cisplatin (Cis)-Related Immunomodulation and Efficacy with Atezolizumab + Cis- vs Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer (mUC)
- ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC)
- ESMO 2021: High- vs Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer (NABUCCO Cohort 2)
- ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer: AURA Trial
- ESMO 2021: Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer
ESMO 2021 Kidney Cancer
- ESMO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- ESMO 2021: Antibiotic Therapy and Outcome from Nivolumab in Metastatic Renal Cell Carcinoma (mRCC) Patients: Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study
- ESMO 2021: Are Adjuvant Immune Checkpoint Inhibitors a Standard of Care for Operable High-Risk Urothelial and Kidney Cancer? No
- ESMO 2021: Are Adjuvant Immune Checkpoint Inhibitors a Standard of Care for Operable High-Risk Urothelial and Kidney Cancer? Yes
- ESMO 2021: Current Status of Personalized Therapy in Metastatic Renal Cell Carcinoma
ESMO 2021 Testicular and Penile Cancer
- ESMO 2021: Invited Discussant: Decreasing Morbidity for the Treatment of Stage II Seminoma
- ESMO 2021: Single-Dose Carboplatin Followed by Involved-Node Radiotherapy As Curative Treatment for Seminoma Stage IIA/B: Efficacy Results From the International Multicenter Phase II Trial SAKK 01/10
- ESMO 2021: A Prospective Phase II Trial of Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors: The CABA-GCT Study
- ESMO 2021: A Prospective Phase II Trial of Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors: The CABA-GCT Study
- ESMO 2021: MicroRNA in the Management of Testicular Cancer